Olema (OLMA) news
Recent news
Olema Pharmaceuticals Q2 EPS USD -0.61
Olema Pharmaceuticals Inc. (NASDAQ:OLMA) reported its Q2 2026 earnings on August 10, 2026, with an earnings per share (EPS) of -$0.61, missing the consensus estimate of -$0.53 by $0.08. This marks a continued period of negative earnings for the clinical-stage biopharmaceutical company, which…
AInvest Wire · Aug 10, 2026Olemia Pharmaceuticals completes enrollment in Phase 3 Opera-01 trial; top-line data expected Q1 2027
Olema Oncology has announced the completion of enrollment in its Phase 3 OPERA-01 clinical trial, which is evaluating palazestrant (OP-1250) as a monotherapy for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast…
AInvest Wire · Aug 10, 2026Olema Pharmaceuticals Q2 income from operations USD -67.179 million
AInvest Wire · Aug 10, 2026BW LPG 1Q EPS $1.08, est. $1.13
BW LPG Limited (NYSE: BWLP, OSE: BWLPG.OL) reported earnings per share (EPS) of $1.08 for the first quarter of 2026, according to a regulatory filing on June 2, 2026. This result fell slightly short of the estimated EPS of $1.13. The company attributed the performance to strong shipping operations…
AInvest Wire · Jun 2, 2026Olema Pharmaceuticals GAAP EPS of -$0.54 beats by $0.01
AInvest Wire · Aug 6, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.